Tsuboi, Yoshio

Neuropathology of variants of progressive supranuclear palsy

Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 386

Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease

Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders

Gut microbiota and healthParkinson's Disease Mechanisms and Treatments

Cited by 370

Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder

Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · mSystems

Gut microbiota and healthParkinson's Disease Mechanisms and Treatments

Cited by 133

Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)

Wszolek, Z. K., Tsuboi, Y., Ghetti, B., Pickering-Brown, S., Baba, Y., & Cheshire, W. P. (2006) · Orphanet Journal of Rare Diseases

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 128

Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease

Nishiwaki, H., Ito, M., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Yoshida, T., Hanada, H., Takeuchi, I., et al. (2022) · npj Parkinson's Disease

Gut microbiota and healthParkinson's Disease Mechanisms and Treatments

Cited by 116

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)

Yamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses

T-cell and Retrovirus StudiesCervical and Thoracic Myelopathy

Cited by 31

Altered Gut Microbiota in Parkinson’s Disease Patients with Motor Complications

Takahashi, K., Nishiwaki, H., Ito, M., Iwaoka, K., Takahashi, K., Suzuki, Y., Taguchi, K., Yamahara, K., Tsuboi, Y., Kashihara, K., et al. (2022) · Parkinsonism & Related Disorders

Parkinson's Disease Mechanisms and TreatmentsGut microbiota and health

Cited by 29

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Tamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology

T-cell and Retrovirus StudiesInfectious Diseases and Tuberculosis

Cited by 29

Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy

Sato, T., Nagai, M., Watanabe, O., Misu, T., Takenouchi, N., Ohkubo, R., Ishihara, S., Tsuboi, Y., Katsuno, M., Nakagawa, M., et al. (2024) · Journal of Neurology

T-cell and Retrovirus StudiesInfectious Diseases and Tuberculosis

Cited by 21